Keiichi Ota

1.9k total citations · 2 hit papers
35 papers, 1.4k citations indexed

About

Keiichi Ota is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Keiichi Ota has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Keiichi Ota's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (14 papers) and HER2/EGFR in Cancer Research (6 papers). Keiichi Ota is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (14 papers) and HER2/EGFR in Cancer Research (6 papers). Keiichi Ota collaborates with scholars based in Japan, United States and China. Keiichi Ota's co-authors include Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto, Koichi Azuma, Koichi Takayama, Koichiro Matsumoto, Shinzo Takamori, Tomoaki Hoshino, Satoshi Hattori and Akihiko Kawahara and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Keiichi Ota

33 papers receiving 1.4k citations

Hit Papers

Association of PD-L1 overexpression with activating EGFR ... 2014 2026 2018 2022 2014 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
    2014 525 citations Koichi Azuma, Keiichi Ota et al. Annals of Oncology profile →
  2. Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
    2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers

Keiichi Ota
Ruochen Li China
Zhenbin Shen China
Remi Adelaiye‐Ogala United States
Nikolas G. Balanis United States
Wataru Sakamoto Japan
Marzena Walkiewicz Australia
Carl Christoph Schimanski Germany
Ichidai Tanaka Japan
Qingqing Ding United States
Ruochen Li China
Keiichi Ota
Citations per year, relative to Keiichi Ota Keiichi Ota (= 1×) peers Ruochen Li

Countries citing papers authored by Keiichi Ota

Since Specialization
Citations

This map shows the geographic impact of Keiichi Ota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiichi Ota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiichi Ota more than expected).

Fields of papers citing papers by Keiichi Ota

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keiichi Ota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiichi Ota. The network helps show where Keiichi Ota may publish in the future.

Co-authorship network of co-authors of Keiichi Ota

This figure shows the co-authorship network connecting the top 25 collaborators of Keiichi Ota. A scholar is included among the top collaborators of Keiichi Ota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keiichi Ota. Keiichi Ota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yoneshima, Yasuto, Koji Okamura, Toyoshi Yanagihara, et al.. (2023). MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Science. 114(10). 4101–4113. 4 indexed citations
3.
Inoue, Hiroyuki, Yoshimasa Shiraishi, Hiroyuki Ando, et al.. (2023). Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors. Lung Cancer. 181. 107264–107264. 8 indexed citations
4.
Okamura, Koji, Hiroyuki Inoue, Kentaro Tanaka, et al.. (2022). Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. Cancer Science. 114(3). 1095–1107. 5 indexed citations
5.
Iwama, Eiji, Keiichi Ota, Hiroyuki Inoue, et al.. (2022). Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer. 175. 101–111. 5 indexed citations
6.
Yoneshima, Yasuto, Mikiko Hashisako, Norikazu Matsuo, et al.. (2022). Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. Translational Lung Cancer Research. 11(11). 2208–2215. 8 indexed citations
7.
Liu, Renpeng, Keiichi Ota, Eiji Iwama, et al.. (2021). Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib. Lung Cancer. 158. 156–161. 4 indexed citations
8.
Hayashi, Hidetoshi, Shunichi Sugawara, Yasushi Fukuda, et al.. (2021). A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research. 28(5). 893–902. 49 indexed citations
9.
10.
Inoue, Hiroyuki, Yasuto Yoneshima, Eiji Iwama, et al.. (2021). Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer. Lung Cancer. 155. 144–150. 15 indexed citations
11.
Inoue, Hiroyuki, Kentaro Tanaka, Eiji Iwama, et al.. (2021). Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. Translational Lung Cancer Research. 10(6). 2475–2486. 16 indexed citations
12.
Yoneshima, Yasuto, Keiichi Ota, Kohei Otsubo, et al.. (2019). Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. Clinical Lung Cancer. 21(1). e21–e24. 4 indexed citations
13.
Yoneshima, Yasuto, Kayo Ijichi, Keiichi Ota, et al.. (2018). PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer. 118. 36–40. 76 indexed citations
14.
Kan‐o, Keiko, Koichiro Matsumoto, Satoru Fukuyama, et al.. (2017). Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism. Biochemical and Biophysical Research Communications. 494(1-2). 242–248. 10 indexed citations
15.
Ota, Keiichi, Yoshimasa Shiraishi, Taishi Harada, et al.. (2017). OA08.02 Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101). Journal of Thoracic Oncology. 12(1). S271–S272. 10 indexed citations
16.
Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →
17.
Li, Heyan, Shuo Wang, Koichi Takayama, et al.. (2015). Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88(1). 1–8. 32 indexed citations
18.
Azuma, Koichi, Keiichi Ota, Akihiko Kawahara, et al.. (2014). Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of Oncology. 25(10). 1935–1940. 525 indexed citations breakdown →
19.
Furuyama, Kazuto, Taishi Harada, Eiji Iwama, et al.. (2013). Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors. Cancer Science. 104(5). 584–589. 43 indexed citations
20.
Ota, Keiichi, et al.. (1976). Decrease in litter weight gain and in progesterone secretion in lactating rats treated with antiserum to rat prolactin. Reproduction. 47(2). 347–349. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruochen Li Breakdown of academic impact, for papers by Zhenbin Shen Breakdown of academic impact, for papers by Remi Adelaiye‐Ogala Breakdown of academic impact, for papers by Nikolas G. Balanis Breakdown of academic impact, for papers by Wataru Sakamoto Breakdown of academic impact, for papers by Marzena Walkiewicz Breakdown of academic impact, for papers by Carl Christoph Schimanski Breakdown of academic impact, for papers by Ichidai Tanaka Breakdown of academic impact, for papers by Qingqing Ding
Rankless by CCL
2026